The UK-based pharmaceutical company, GlaxoSmithKline, intends to reopen negotiations with the Department of Health, for the reversal of decision by the National Health Service regarding GSK’s cancer medicine Tyverb.

The company is likely to offer a “price-volume” deal, which would address concerns of the government’s medicine advisory board regarding the high cost of the drug in comparison with its benefits to the patients.

GSK’s Tyverb has already been approved by the European regulator for treatment of late-stage breast cancer. It was launched last year in the US under the name Tyverb, but met with greater resistance in the UK.

A ruling, by the National Institute for Health and Clinical excellence (Nice), against Tyverb, halted the use of medicine in the UK. In fact, Nice made series of rejections of cancer drugs for high prices, including Avastin from Roche of Switzerland and Erbitux from Merck of Germany.

GSK has come out with an innovative price proposal for Tyverb. It is suggesting NHS to put a cap on the total cost of the medicine irrespective of number of patients using it. It proposes a fixed price which would cover the drug cost for several thousand patients. GSK estimates that 70% of the UK patients who fail to get relief through other treatments including Herceptin, would benefit from Tyverb.

Things to consider:
Try our new Health Supplements
do you have Acne Scarring
Deep Tissue Massage Dublin
Digital Hearing Aids
Champix